# Shanghai Miracogen

Source: https://onco.cc/companies/shanghai-miracogen/  
OnCo record `shanghai-miracogen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai Miracogen is a Chinese antibody-drug conjugate developer whose HER2 conjugate MRG002 has been tested across breast, stomach, bladder and biliary cancers and whose EGFR conjugate MRG003 targets head and neck and nasopharyngeal cancer.

## Summary

Shanghai Miracogen builds antibody-drug conjugates with site-specific conjugation and auristatin payloads. MRG002 links a HER2 antibody to monomethyl auristatin E and has been studied in HER2-positive and HER2-low breast cancer, gastric cancer, urothelial carcinoma and biliary tract cancer. MRG003 targets EGFR in nasopharyngeal and head and neck squamous carcinomas, and MRG004A targets tissue factor in pancreatic cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Miracogen; Shanghai Miracogen Inc.; 美雅珂生物
- Tags: drug-maker
- HQ: Shanghai
- Type: biotech
- Website: https://www.miracogen.com/

## Sources

- Official website: https://www.miracogen.com/

## Connected records

- drugs: [MRG002](https://onco.cc/drugs/mrg002/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-miracogen.json